What is Ro?
Ro operates as a comprehensive telehealth platform designed to streamline the patient experience by connecting individuals with licensed healthcare providers for a variety of personal health needs. The company offers a diverse suite of services, including treatments for weight loss, sexual health, hair loss, fertility, and skin improvement. By integrating FDA-approved medications and supplements—such as GLP-1s—directly into its service model, Ro provides a seamless, end-to-end solution for patients seeking convenient and affordable care.
The company's market position is defined by its focus on patient-centric innovation, allowing users to manage complex health goals from the comfort of their homes. By leveraging technology to remove traditional barriers to entry in the healthcare system, Ro has built a substantial membership base, positioning itself as a trusted partner in the evolving landscape of digital medicine and personal wellness.
How much funding has Ro raised?
Ro has raised a total of $1B across 6 funding rounds:
Angel/Seed
$3.1M
Series A
$88M
Series B
$85M
Series C
$200M
Series D
$500M
Unspecified
$150M
Angel/Seed (2017): $3.1M with participation from Box Group, Initialized Capital, Slow Ventures, and General Catalyst
Series A (2018): $88M led by Tusk Ventures, General Catalyst, FirstMark Capital, Sinai Ventures, SignalFire, Initialized Capital, Torch Capital, BoxGroup, and Slow Ventures
Series B (2019): $85M supported by General Catalyst, Box Group, Slow Ventures, FirstMark Capital, and Initialized Capital
Series C (2020): $200M featuring TQ Ventures, Initialized Capital, General Catalyst, Torch, BoxGroup, SignalFire, 3L, FirstMark Capital, and The Chernin Group
Series D (2021): $500M backed by The Baupost Group, General Catalyst, FirstMark Capital, Dragoneer Investment Group, TQ Ventures, ShawSpring Partners, SignalFire, Altimeter Capital, Radcliff, BoxGroup, Torch Capital, and 776
Unspecified (2022): $150M with participation from FirstMark Capital, General Catalyst, and ShawSpring Partners
Key Investors in Ro
General Catalyst
General Catalyst is a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors, including healthcare and technology.
FirstMark Capital
FirstMark Capital is a New York-based firm that provides strategic capital and operational support to high-growth companies in the information and technology sectors.
Initialized Capital
Initialized Capital is a venture firm dedicated to supporting founders from the seed stage through long-term success across various sectors, including health and enterprise SaaS.
What's next for Ro?
Looking ahead, Ro is well-positioned to leverage its recent strategic investment to deepen its service offerings and expand its reach within the competitive healthtech landscape. The company's focus remains on scaling its infrastructure to support a growing patient base while maintaining the high standards of care that have defined its brand. As the telehealth industry matures, Ro is expected to prioritize the integration of advanced diagnostic tools and personalized treatment plans, further differentiating its platform from traditional healthcare providers.
The continued support from institutional investors suggests a long-term commitment to Ro's vision of a more accessible, patient-first healthcare ecosystem. Future growth will likely involve strategic partnerships and potential diversification into new therapeutic areas, ensuring that the company remains at the forefront of the digital health revolution.
